3191 results for «684»
3191 results
Supraflex for high-risk patients and lesions: from practice to evidence-based medicine proven through FIRE and COMPARE
20 May 2025 – From EuroPCR 2025
Discover the latest evidence on the Supraflex thin-strut sirolimus DES in complex cases—from small vessels and diabetes to STEMI—supported by OCT analysis. This session highlights Supraflex’s performance in high bleeding risk and elderly patients, featuring data from FIRE, COMPARE, EARTH HBR, and Cruz Senior studies. Get...
Hostile access for TAVI procedure
21 May 2025 – From EuroPCR 2025
This session addresses the challenges of hostile vascular access in TAVI procedures. Learn to identify difficult access sites through pre-operative imaging, explore alternative approaches such as axillary access, techniques to overcome iliac access difficulties, and management of peri- and post-operative complications by vascular surgeons.
Align for the future with next gen Myval transcatheter heart valve series
16 Nov 2025 – From PCR London Valves 2025
Discover how the latest Myval transcatheter heart valve (THV) innovations are shaping TAVI outcomes. This PCR London Valves 2025 session highlights the clinical evidence behind the next-gen Myval THV series, best practices for implantation, and upcoming innovations set to improve patient care. Learn step-by-step techniques for deploying Myval...
Advancing structural heart with 3D ICE and device guidance
17 Nov 2025 – From PCR London Valves 2025
This PCR London Valves 2025 session explores how 3D TEE, 3D intracardiac echocardiography (ICE), and DeviceGuide technology sharpen procedural accuracy, strengthen operator confidence, and streamline decision-making in real time.
You’ll see how clearly defined team roles enhance both safety and efficiency, and how thoughtful workflow integration can reduce...
A new era for aortic regurgitation: how new guidelines and dedicated devices for AR will redefine treatment
18 Nov 2025 – From PCR London Valves 2025
This session examines the evolving treatment landscape for aortic regurgitation (AR) in light of new ESC guidelines and dedicated devices such as the JenaValve Trilogy System. It provides an in-depth look at refined diagnosis, optimized treatment strategies, and presents real-world data and clinical cases that highlight...
Cardiovalve hits the TARGET: advancing transcatheter valve replacement
18 Nov 2025 – From PCR London Valves 2025
This session highlights the features and procedural steps of the next-generation Cardiovalve systems for tricuspid and mitral valve replacement. It reviews interim results from the TARGET study, emphasizing echocardiographic findings and reverse remodeling effects, and discusses best practices for patient selection and the learning pathway to...
Management of mitral regurgitation patients undergoing TMVI screening
13 Jan 2022
This study's results emphasise the strengths and limitations of transcatheter mitral valve implantation (TMVI) as a novel and promising therapy providing predictable elimination of MR in most patients, by S. Ludwig et al.
PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial
18 May 2021
Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...
5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)
01 Apr 2025
Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.
Author
30 years of primary PCI – a tale of perseverance
16 May 2023
Over the last 30 years, primary PCI (pPCI) has evolved from an experimental ‘rescue’ intervention to an essential routine procedure – performed daily in cathlabs around the world – which is responsible for saving millions of lives. However, its path to success was far from smooth.
Transcatheter vs surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut Low Risk trial
05 Mar 2023
Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.
Author
